- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What You May Have Missed at RAD 2023
The Revolutionizing Atopic Dermatitis (RAD) meeting took place April 29 through May 1 in Washington, DC, with The American Journal of Managed Care® there to cover the meeting. Some of the top news you may have missed is right below.
These are the top news items from the 2023 Revolutionizing Atopic Dermatitis (RAD) meeting, which took place in Washington, DC, from April 29 to May 1.
Panel Focuses on Burgeoning Therapies in Atopic Dermatitis
A panel held at RAD 2023 reviewed therapies to expect within the next year for the treatment of atopic dermatitis (AD) as well as investigational therapies currently undergoing trials.
Symposium Highlights New Research on JAK, PDE-4 Inhibitors
Janus kinase (JAK) and phosphodiesterase-4 (PDE-4) inhibitors were primary topics covered at the third symposium at the RAD fifth annual conference.
Dr Melinda Gooderham Discusses Emerging Therapies in Atopic Dermatitis
Melinda Gooderham, MSc, MD, FRCPC, dermatologist and clinical researcher at Peterborough Regional Health Centre, discusses emerging topical and biologic therapies expected to be available later this year.
Dr Robert Sidbury: How to Treat Facial Atopic Dermatitis in Infants
Robert Sidbury, MD, MPH, professor of pediatrics at Seattle Children's Hospital, discussed treatment approaches for AD of the face in infancy.
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
New AI Tool Identifies Undiagnosed PNH in Health Records
October 30th 2024The machine learning model shows promise in detecting paroxysmal nocturnal hemoglobinuria (PNH) by assessing electronic health records (EHR) data, potentially transforming the diagnostic landscape for rare diseases.
Read More
Zanubrutinib More Effective Than Ibrutinib in Treating Patients With Relapsed/Refractory CLL, SLL
October 30th 2024The long-term response rate for zanubrutinib was better than ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Read More
